Slides
Page 1
Decision Regarding the Termination of the Supply Agreement with CSL Plasma Hikaru Samejima Chief Executive Officer Terumo Corporation October 8, 2026
Page 2
Primary colors Secondary colors Caution Terumo Green Main text Sub text ©TERUMO CORPORATION 2 Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. Information about products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.
Page 3
©TERUMO CORPORATION 3 Primary colors Secondary colors Caution Terumo Green Main text Sub text Decision Regarding the CSL Plasma Supply Agreement Agreed to terminate the current supply agreement with CSL Plasma, gradually wind down supply and focus TBCT resources on other businesses. Key Decisions • Agreed to terminate the current supply agreement with CSL Plasma effective today • Implement the agreed transition plan and support the orderly wind- down of supply activities • Expect to record approximately US$610 million in impairment charges and related costs in FY26 Background • Decision follows CSL Plasma’s August 2026 notification to transition a portion of its collection centers to another technology platform, citing areas where Rika did not fully meet customer expectations, among other factors. • Following the notification, both parties continued discussions regarding future contractual arrangement Rationale for the Decision • After reassessing the long-term business outlook, required future investments, and expected returns, TBCT concluded that it is more appropriate to focus its resources on other businesses with larger market opportunities and stronger profitability • Plasma Innovations business is reported within TBCT • CSL Plasma is the primary customer of the PI business in TBCT, accounting for the vast majority of its revenue • 2021: Strategic collaboration between TBCT and CSL Plasma began • 2022: The Rika Plasma Donation System received U.S. FDA clearance. TBCT established a new manufacturing facility in Colorado to produce disposables, with approximately US$250 million invested in the business. Overview of the Plasma Innovations (PI) Business
Page 4
©TERUMO CORPORATION 4 Primary colors Secondary colors Caution Terumo Green Main text Sub text Financial and FY26 Guidance Impact FY26 guidance revised downward to reflect approximately US$610 million of impairment charges and related costs. Financial Impact Impact on FY26 Guidance • Primarily related to manufacturing facilities, equipment and other fixed assets Impairment Charges US$450M1 (Non-cash) Related Costs US$160M1 (Transition, termination and restructuring- related costs) • Business losses incurred during the transition period, contract termination costs, restructuring expenses and employee-related costs (100M JPY) FY26 Previous guidance FY26 Revised guidance Sales 12,390 12,295 AOP (%) 2,745 (22.2%) 2,745 (22.2%) OP (%) 2,575 (20.8%) 1,600 (13.0%) Net Profit 1,931 1,200 Dividend/Share 36Yen 36Yen 1. Both amounts are current estimates and are subject to change depending on future developments
Page 5
©TERUMO CORPORATION 5 Primary colors Secondary colors Caution Terumo Green Main text Sub text Our Assessment of the PI Business While Rika has created substantial value, changes in the business environment made originally anticipated economic returns increasingly difficult to achieve. • Entered the source plasma market through a collaboration with CSL Plasma to address the industry’s need for innovation in plasma collection • Expected to drive growth through a solution business in collaboration with CSL Plasma • The Rika Plasma Donation System introduced a next-generation technology that disrupted the source plasma collection market • Customer value in plasma collection depends on reliability, ease of use, software, connectivity and operational support, in addition to collection performance • Delivering this broader value proposition required more investment and time than originally anticipated • Volume growth and profitability improvement were delayed by more than two years Original Strategic Rationale Business Environment Changes and Impact
Page 6
©TERUMO CORPORATION 6 Primary colors Secondary colors Caution Terumo Green Main text Sub text 13.0% 15.0% 17.0% 19.0% 21.0% 23.0% 25.0% FY26 FY27 FY28 FY29 FY30 FY31 Sales AOP% TBCT Growth Drivers and Profitability Outlook Through the reshaping of the TBCT portfolio, resources will be concentrated on the core businesses with larger market opportunities and stronger profitability. As a result, TBCT profitability is expected to improve from FY27 onward. Key Growth and Profitability Drivers for TBCT TBCT Profitability Outlook • Continued growth of core blood processing business, led by apheresis collection and automated whole blood processing. • Expansion of therapeutic apheresis across disease-states and geographies. • Enhanced operational excellence through optimization of manufacturing, R&D and organizational capabilities. • TBCT profitability is expected to improve from FY27 onward, supported by portfolio reshaping and increased focus on core businesses Note: FY26 reflects the full-year guidance announced in May 2026. 16% Trima AccelTM ReveosTM Spectra OptiaTM
Page 7
©TERUMO CORPORATION 7 Primary colors Secondary colors Caution Terumo Green Main text Sub text Key Takeaways Management’s Reflection Commitment to Ongoing Portfolio Transformation Further details will be provided as part of GS31, our next five-year growth strategy (December 15)